Fedele, P.; Landriscina, M.; Moraca, L.; Gadaleta-Caldarola, A.; Cusmai, A.; Giuliani, F.; Chiuri, V.; Giotta, F.; Pinto, A.; Mirisola, V.;
et al. Standard Versus Reduced CDK4/6 Inhibitor Therapy in Elderly Patients with Metastatic Hormone Receptor-Positive, HER2-Negative Breast Cancer: An Observational Multicenter Study. J. Clin. Med. 2024, 13, 7441.
https://doi.org/10.3390/jcm13237441
AMA Style
Fedele P, Landriscina M, Moraca L, Gadaleta-Caldarola A, Cusmai A, Giuliani F, Chiuri V, Giotta F, Pinto A, Mirisola V,
et al. Standard Versus Reduced CDK4/6 Inhibitor Therapy in Elderly Patients with Metastatic Hormone Receptor-Positive, HER2-Negative Breast Cancer: An Observational Multicenter Study. Journal of Clinical Medicine. 2024; 13(23):7441.
https://doi.org/10.3390/jcm13237441
Chicago/Turabian Style
Fedele, Palma, Matteo Landriscina, Lucia Moraca, Arianna Gadaleta-Caldarola, Antonio Cusmai, Francesco Giuliani, Vincenzo Chiuri, Francesco Giotta, Antonello Pinto, Valentina Mirisola,
and et al. 2024. "Standard Versus Reduced CDK4/6 Inhibitor Therapy in Elderly Patients with Metastatic Hormone Receptor-Positive, HER2-Negative Breast Cancer: An Observational Multicenter Study" Journal of Clinical Medicine 13, no. 23: 7441.
https://doi.org/10.3390/jcm13237441
APA Style
Fedele, P., Landriscina, M., Moraca, L., Gadaleta-Caldarola, A., Cusmai, A., Giuliani, F., Chiuri, V., Giotta, F., Pinto, A., Mirisola, V., & Gadaleta-Caldarola, G.
(2024). Standard Versus Reduced CDK4/6 Inhibitor Therapy in Elderly Patients with Metastatic Hormone Receptor-Positive, HER2-Negative Breast Cancer: An Observational Multicenter Study. Journal of Clinical Medicine, 13(23), 7441.
https://doi.org/10.3390/jcm13237441
